RRx-001, a first-in-class small molecule inhibitor of MYC and a downregulator of CD47, is an "erythrophagoimmunotherapeutic"

RRx-001, a first-in-class small molecule inhibitor of MYC and a downregulator of CD47, is an "erythrophagoimmunotherapeutic"

The main mechanism of action of RRx-001, a pharmaceutically unprecedented sui generis Phase 3 small molecule that is derived from the aerospace industry, is clarified. RRx-001 has demonstrated anticancer activity through antiangiogenic, immune, epigenetic, antioxidant, apoptotic and nitric oxide (NO...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Oncoimmunology 2020-01, Vol.9 (1), p.1746172-1746172
Hauptverfasser: Oronsky, Bryan, Carter, Corey A., Caroen, Scott, Scribner, Curtis, Oronsky, Arnold, Reid, Tony R.
Format: Artikel
Sprache:eng
Schlagworte:
Back Matter
CD47
erythrophagoimmunotherapeutic
hemoglobin
Immunotherapy
MYC
small molecule
tumor associated macrophage
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The main mechanism of action of RRx-001, a pharmaceutically unprecedented sui generis Phase 3 small molecule that is derived from the aerospace industry, is clarified. RRx-001 has demonstrated anticancer activity through antiangiogenic, immune, epigenetic, antioxidant, apoptotic and nitric oxide (NO) pathways, resulting in its pleiomorphic description as an antiangiogenic/vascular normalizer.
ISSN:2162-402X
2162-4011
2162-402X
DOI:10.1080/2162402X.2020.1746172